Climb Bio to Present at Upcoming Investor Conferences

GlobeNewswire

31 Oct 2024

climb-400x400 (002).jpg

WELLESLEY, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences detailed below.

Guggenheim Securities Healthcare Innovation Conference
Format: Fireside chat and one-on-one investor meetings
Date: November 11-12, 2024

Stifel 2024 Healthcare Conference
Format: Fireside chat and one-on-one investor meetings
Date: November 18-19, 2024

36^th Annual Piper Sandler Healthcare Conference
Format: Fireside chat and one-on-one investor meetings
Date: December 3-5, 2024

7^th Annual Evercore ISI HealthCONx Conference
Format: Fireside chat and one-on-one investor meetings
Date: December 3-5, 2024

The presentations will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at climbbio.com.

About Climb Bio, Inc.
Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com.

Investors
Chris Brinzey
ICR Healthcare
chris.brinzey@ICRhealthcare.com
339-970-2843

Media
Jon Yu
ICR Healthcare
jon.yu@icrhealthcare.com
475-395-5375

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2479970294"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2479970294\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2479970294?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/HPitbdp9N5zE.42TwFDHng--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b6e600f3e302fa66aa6dc30453d5e383","is_english":true,"pubTime":"2024-10-31 19:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2479970294","market":"us","top_or_hot":-1,"title":"Climb Bio to Present at Upcoming Investor Conferences","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/Q3v3mf.SxwiOzmB2SPXVUg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/96b5fbbb4dd8bc4bbccc298a6909629c\" title=\"climb-400x400 (002).jpg\" vspace=\"5\"/>\n<p>WELLESLEY, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences detailed below.</p>\n<p><strong>Guggenheim Securities Healthcare Innovation Conference</strong><br/>Format: Fireside chat and one-on-one investor meetings<br/>Date: November 11-12, 2024<br/><br/></p>\n<p><strong>Stifel 2024 Healthcare Conference</strong><br/>Format: Fireside chat and one-on-one investor meetings<br/>Date: November 18-19, 2024<br/><br/></p>\n<p><strong>36</strong><sup><strong>th</strong></sup><strong> Annual Piper Sandler Healthcare Conference</strong><br/>Format: Fireside chat and one-on-one investor meetings<br/>Date: December 3-5, 2024<br/><br/></p>\n<p><strong>7</strong><sup><strong>th</strong></sup><strong> Annual <a href=\"https://laohu8.com/S/EVR\">Evercore</a> ISI HealthCONx Conference</strong><br/>Format: Fireside chat and one-on-one investor meetings<br/>Date: December 3-5, 2024<br/><br/></p>\n<p>The presentations will be webcast live and available for replay under “News &amp; Events” in the Investors section of the Company's website at climbbio.com.</p>\n<p><strong>About Climb Bio, Inc. </strong><br/>Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com.<br/></p>\n<p><strong>Investors</strong><br/>Chris Brinzey <br/>ICR Healthcare<br/>chris.brinzey@ICRhealthcare.com<br/>339-970-2843<br/><br/><br/><br/></p>\n<p><strong>Media</strong><br/>Jon Yu<br/>ICR Healthcare<br/>jon.yu@icrhealthcare.com<br/>475-395-5375<br/><br/><br/><br/></p>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Climb Bio to Present at Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClimb Bio to Present at Upcoming Investor Conferences\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-31 19:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/climb-bio-present-upcoming-investor-110000381.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WELLESLEY, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences ...</p>\n\n<a href=\"https://finance.yahoo.com/news/climb-bio-present-upcoming-investor-110000381.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/climb-bio-present-upcoming-investor-110000381.html","article_id":"2479970294","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/HPitbdp9N5zE.42TwFDHng--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b6e600f3e302fa66aa6dc30453d5e383"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479970294","pubTimestamp":1730372400,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"WELLESLEY, Mass., Oct. 31, 2024  -- Climb Bio, Inc. , announced that members of its executive team are scheduled to participate in the upcoming investor conferences detailed below.Guggenheim Securities Healthcare Innovation ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: November 11-12, 2024. Stifel 2024 Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: November 18-19, 2024. 7th Annual Evercore ISI HealthCONx ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: December 3-5, 2024. The presentations will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at climbbio.com.About Climb Bio, Inc. Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Climb Bio将出席即将举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLYM":0.9},"content_text":"WELLESLEY, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences detailed below.\nGuggenheim Securities Healthcare Innovation ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: November 11-12, 2024\nStifel 2024 Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: November 18-19, 2024\n36th Annual Piper Sandler Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: December 3-5, 2024\n7th Annual Evercore ISI HealthCONx ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: December 3-5, 2024\nThe presentations will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at climbbio.com.\nAbout Climb Bio, Inc. Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com.\nInvestorsChris Brinzey ICR Healthcarechris.brinzey@ICRhealthcare.com339-970-2843\nMediaJon YuICR Healthcarejon.yu@icrhealthcare.com475-395-5375","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}